However, these antibodies targeting CTLA-4 have shown suboptimal antitumor activity in BC and severe immunotherapy-related adverse effects (irAEs) that can in great part contribute to lysosomal degradation of CTLA-4 [197]. This evidence concerns the gene CTLA4 and breast cancer.